Japan approves Bristol-Myers' nivolumab, hep C combo; CMS tweaks Sunshine Act;

> Bristol-Myers Squibb's ($BMS) Opdivo (nivolumab), an immuno-oncology drug for advanced melanoma, has scored its first regulatory green light, grabbing Japanese approval. Release

> Japan has approved Bristol-Myers Squibb's ($BMS) next-gen hepatitis C cocktail, made up of Daklinza and Sunvepra. Release

> The Centers for Medicare & Medicaid Services (CMS) announced plans to enact changes to the Open Payments program, including the Sunshine exemption for continuing medical education. More

> AstraZeneca ($AZN) will hold a Twitter chat to answer questions about its home-delivery program. Blog

> Celgene's ($CELG) Imnovid, a multiple myeloma drug, was rejected by the Scottish Medicines Consortium despite the recognition of its ability to significantly improve chances of survival. Sanofi's ($SNY) Lemtrada and Roche's ($RHHBY) MabThera both received positive recommendations. Story

> Takeda Pharmaceutical is taking heat for publishing a 74-page report on a probe of a "misleading" ad for its Blopress high blood pressure medicine--exclusively in Japanese. More (sub. req.)

And Finally... Taiwan's Gala Television has been fined $200,000 for using the name of a Taiwanese pharmaceutical company as a title sponsor for a singing contest. News

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.